Pharma News

The day in pharma, read in minutes.

Updated Nov 17, 2026

Latest news

11 stories
NewsNew

UCB Gains FDA Approval for Klygefa as First Dual-Binding Nanobody C5 Inhibitor

UCB's Klygefa becomes the first dual-binding nanobody C5 inhibitor approved in the US for generalized myasthenia gravis, delivered via subcutaneous autoinjector.

Vaibhavi M.Nov 17, 2026Read more
UCB Gains FDA Approval for Klygefa as First Dual-Binding Nanobody C5 Inhibitor
NewsNew

Novartis Gains CHMP Positive Opinion for Cosentyx in Adolescent Hidradenitis Suppurativa

Novartis's Cosentyx receives CHMP positive opinion for adolescent HS, triggering label expansion obligations across batch release, packaging, and pharmacovigilance in Europe.

Vaibhavi M.Nov 16, 2026Read more
Novartis Gains CHMP Positive Opinion for Cosentyx in Adolescent Hidradenitis Suppurativa
News

Evotec Secures $2.9 Million Gates Foundation Grant to Extend Stem Cell-Based Fetal Safety Screening

Evotec receives a $2.9M Gates Foundation grant to extend its hiPSC-based fetal safety screening platform for global health drug programs.

Vaibhavi M.Nov 16, 2026Read more
Evotec Secures $2.9 Million Gates Foundation Grant to Extend Stem Cell-Based Fetal Safety Screening
News

EMA CHMP Recommends Seven Medicines at November 2026 Meeting

CHMP recommends seven new medicines at November 2026 meeting, including two insulin aspart biosimilars and generic ruxolitinib, advancing EU market entry timelines.

Vaibhavi M.Nov 13, 2026Read more
EMA CHMP Recommends Seven Medicines at November 2026 Meeting
News

Reviva Secures USPTO Track 1 Review for Brilaroxazine

Reviva Pharmaceuticals gains USPTO Track 1 priority examination for a new brilaroxazine formulation patent, with exclusivity potentially extending to 2046.

Vaibhavi M.Nov 13, 2026Read more
Reviva Secures USPTO Track 1 Review for Brilaroxazine
News

Sutro Biopharma Advances Three ADC Programs Toward Clinic

Sutro Biopharma advances three site-specific ADC programs toward or into Phase 1, with cell-free conjugation enabling precise DAR control across dual-payload formats.

Vaibhavi M.Nov 13, 2026Read more
Sutro Biopharma Advances Three ADC Programs Toward Clinic
News

Immix Biopharma Appoints Dual SVPs Ahead of NXC-201 BLA

Immix Biopharma builds out CMC and regulatory leadership ahead of a mid-2027 NXC-201 BLA submission, with 89% complete response rate data heading to ASH.

Vaibhavi M.Nov 13, 2026Read more
Immix Biopharma Appoints Dual SVPs Ahead of NXC-201 BLA
News

Codexis Achieves 100-Gram Oligonucleotide Scale-Up

Codexis scales ECO Synthesis to 100g oligonucleotide output and targets GMP facility readiness by end of 2027 for early clinical siRNA supply.

Vaibhavi M.Nov 13, 2026Read more
Codexis Achieves 100-Gram Oligonucleotide Scale-Up
News

Eros Apothecary Recalls Honey Supplement Over Tadalafil

Eros Apothecary recalls honey supplement after FDA lab testing detects undeclared tadalafil, flagging e-commerce supply chain oversight gaps.

Vaibhavi M.Nov 13, 2026Read more
Eros Apothecary Recalls Honey Supplement Over Tadalafil
News

Artelo Reports 40% Weight Loss with Semaglutide in Mice

Artelo's ART27.13 achieves ~40% weight loss combined with semaglutide in nonclinical model; U.S. patent protection expected through 2041.

Vaibhavi M.Nov 12, 2026Read more
Artelo Reports 40% Weight Loss with Semaglutide in Mice
News

Grace Therapeutics Advances Dual-Source CMO Strategy

Grace Therapeutics pursues dual-source CMO strategy for GTx-104 after FDA CRL flags CMC deficiencies, with NDA resubmission tied to whichever site clears readiness first.

Vaibhavi M.Nov 12, 2026Read more
Grace Therapeutics Advances Dual-Source CMO Strategy